St. Jude Clinical Trials
-
COVID-19 Pediatric Vaccine Studies
St. Jude is planning to participate in clinical trials to test COVID-19 prevention vaccines in healthy children. Find out more.
-
COVID-19 Vaccine Study ENSEMBLE
St. Jude and UTHSC conducted trials in Memphis for a COVID prevention vaccine for adults. Read about the trial and its early results.
SENDAI: A Phase I Study of Unmodified Live Intranasal Sendai Virus Vaccine in Children and Toddlers: Assessment of Safety and Immunogenicity
Eligibility:
- Child is greater than or equal to twelve (12) months and less than twenty-four (24) months.
- Child has adequate blood, liver and kidney function.
- Child has no history of lung disease, asthma, and hospitalization for respiratory illness, immunodeficiency, sickle cell disease, or any other serious underlying condition.
Collaborative Clinical Trials
GS1269: Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Children and Adolescents Virologically Suppressed on a 2-NRTI-Containing Regimen
Diseases Treated:
Eligibility:
- Participant is HIV-1 infected male or female aged six (6) to less than eight-teen (18) years of age at Baseline.
- Participant is currently on a stable 2-NRTI (TDF containing) regimen that includes a protocol specified 3rd ARV agent for greater than or equal to six (6) consecutive months prior to screening.
- Participant does not have an acquired immunodeficiency syndrome (AIDS) indicator condition with onset within thirty (30) days prior to screening.
P1093: Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents
Diseases Treated:
Eligibility:
- At least 4 weeks old but younger than 18 years old
- Confirmed HIV-1 infection
- Current or past treatment with HIV medications (Children younger than 2 years old may be eligible even if they have not been treated with HIV medications.)
SENDAI: A Phase I Study of Unmodified Live Intranasal Sendai Virus Vaccine in Children and Toddlers: Assessment of Safety and Immunogenicity
Eligibility:
- Child is greater than or equal to twelve (12) months and less than twenty-four (24) months.
- Child has adequate blood, liver and kidney function.
- Child has no history of lung disease, asthma, and hospitalization for respiratory illness, immunodeficiency, sickle cell disease, or any other serious underlying condition.